Acceleron Pharma base_Aktie

Acceleron Pharma base_Gewinn 2025

Acceleron Pharma base_Gewinn

-203.71 number_format_mio USD

components_StockPageHeader__3

XLRN

components_StockPageHeader__4

US00434H1086

components_StockPageHeader__5

A1W5LE

pages_kennzahlen_[key]_[isin]__21

pages_kennzahlen_[key]_[isin]__70

components_DataTable__24components_DataTable__5
2025e-203.71
2024e-159.77
2023e-127.82
2022e-204.43
2021e-247.87
2020-166.03
2019-124.86
2018-118.87
2017-108.45
2016-57.01
2015-63.89
2014-51.26
2013-21.9
2012-32.58
201136.27

components_charts_RevenueChart_0

  • chart_toolbar_3y

  • chart_toolbar_5y

  • chart_toolbar_10y

  • components_charts_BaseChart_0

  • chart_toolbar_max

components_charts_RevenueChart_8
components_charts_RevenueChart_10
components_charts_RevenueChart_9
Details
components_charts_RevenueChart_13

Acceleron Pharma components_charts_RevenueChart_15

components_charts_RevenueChart_14Acceleron Pharma components_charts_RevenueChart_8Acceleron Pharma components_charts_RevenueChart_10Acceleron Pharma components_charts_RevenueChart_9
2025e642.76 number_format_mio undefined0 undefined-203.71 number_format_mio undefined
2024e436.36 number_format_mio undefined0 undefined-159.77 number_format_mio undefined
2023e302.16 number_format_mio undefined0 undefined-127.82 number_format_mio undefined
2022e215.16 number_format_mio undefined0 undefined-204.43 number_format_mio undefined
2021e139.56 number_format_mio undefined0 undefined-247.87 number_format_mio undefined
202092.52 number_format_mio undefined-167.31 number_format_mio undefined-166.03 number_format_mio undefined
201973.99 number_format_mio undefined-136.45 number_format_mio undefined-124.86 number_format_mio undefined
201813.99 number_format_mio undefined-124.41 number_format_mio undefined-118.87 number_format_mio undefined
201713.48 number_format_mio undefined-109.98 number_format_mio undefined-108.45 number_format_mio undefined
201627.77 number_format_mio undefined-66.11 number_format_mio undefined-57.01 number_format_mio undefined
201518.1 number_format_mio undefined-60.88 number_format_mio undefined-63.89 number_format_mio undefined
201414.63 number_format_mio undefined-50.46 number_format_mio undefined-51.26 number_format_mio undefined
201357.23 number_format_mio undefined6.95 number_format_mio undefined-21.9 number_format_mio undefined
201215.25 number_format_mio undefined-28.89 number_format_mio undefined-32.58 number_format_mio undefined
201180.91 number_format_mio undefined38.56 number_format_mio undefined36.27 number_format_mio undefined

components_charts_MarginsChart_0

components_charts_MarginsChart_18
  • chart_toolbar_3y

  • chart_toolbar_5y

  • chart_toolbar_10y

  • components_charts_BaseChart_0

  • chart_toolbar_max

components_charts_MarginsChart_15
components_charts_MarginsChart_17
components_charts_MarginsChart_16
Details
components_charts_MarginsChart_19

Acceleron Pharma components_charts_MarginsChart_21

Acceleron Pharma components_charts_MarginsChart_15Acceleron Pharma components_charts_MarginsChart_16Acceleron Pharma components_charts_MarginsChart_17Acceleron Pharma components_charts_MarginsChart_16
2025e100 %0 %-31.69 %
2024e100 %0 %-36.62 %
2023e100 %0 %-42.3 %
2022e100 %0 %-95.02 %
2021e100 %0 %-177.61 %
2020100 %-180.84 %-179.45 %
2019100 %-184.42 %-168.75 %
2018100 %-889.28 %-849.68 %
2017100 %-815.88 %-804.53 %
2016100 %-238.06 %-205.29 %
2015100 %-336.35 %-352.98 %
2014100 %-344.91 %-350.38 %
2013100 %12.14 %-38.27 %
2012100 %-189.44 %-213.64 %
201198.15 %47.66 %44.83 %

Acceleron Pharma Aktienanalyse

pages_kennzahlen_[key]_[isin]__1

Acceleron Pharma Inc. is a biopharmaceutical company based in Cambridge, Massachusetts. It was founded in 2003 by a group of scientists specializing in drug development in the fields of oncology and hematology. The company's business model is based on the discovery and development of innovative therapeutic solutions, particularly in the areas of oncology and rare diseases. They use a wide range of technologies to identify potential target molecules and test their effectiveness. Acceleron Pharma operates in three different business areas: oncology, hemoglobinopathies, and musculoskeletal diseases. In oncology, the company focuses on developing drugs to treat cancers such as multiple myeloma or pancreatic cancer. The hemoglobinopathies division of Acceleron Pharma develops therapies for patients with rare blood disorders such as beta-thalassemia and sickle cell disease. In the field of musculoskeletal diseases, the company is working on developing therapies for muscle, connective tissue, and joint disorders. One of Acceleron Pharma's key products is the drug Reblozyl, which was developed in collaboration with Bristol Myers Squibb. Reblozyl is the first FDA-approved medication for the treatment of anemia in patients with beta-thalassemia. The company has also entered into a partnership agreement with Celgene to develop medications for the treatment of inflammatory bowel diseases. Acceleron Pharma has also successfully partnered with other major pharmaceutical companies such as Pfizer and Sanofi in the past. Through these partnerships, the company has provided its technology platform for the discovery and development of drugs for various indications such as cancer and muscle diseases. Acceleron Pharma is a fast-growing company dedicated to researching and developing innovative therapies for rare diseases. With a wide range of technologies and a strong pipeline of clinical candidates, the company is well-equipped to treat patients affected by these rare diseases. Acceleron Pharma ist eines der beliebtesten Unternehmen auf Eulerpool.com.

pages_kennzahlen_[key]_[isin]__85

pages_kennzahlen_[key]_[isin]__72

pages_dividenden_[isin]_index__2

components_kpi_EarningFaqs_0

components_kpi_EarningFaqs_1

components_kpi_EarningFaqs_2

components_kpi_EarningFaqs_3

components_kpi_EarningFaqs_4

components_kpi_EarningFaqs_5

components_kpi_EarningFaqs_6

components_kpi_EarningFaqs_7

components_kpi_EarningFaqs_8

components_kpi_EarningFaqs_9

components_kpi_EarningFaqs_10

components_kpi_EarningFaqs_11

components_kpi_EarningFaqs_12

components_kpi_EarningFaqs_13

pages_aktie_[isin]_[key]_index_0

pages_aktie_[isin]_[key]_index_1

pages_aktie_[isin]_[key]_index_2

pages_aktie_[isin]_[key]_index_3

pages_aktie_[isin]_[key]_index_4

pages_aktie_[isin]_[key]_index_5

pages_aktie_[isin]_[key]_index_6

pages_aktie_[isin]_[key]_index_7

pages_aktie_[isin]_[key]_index_8

pages_aktie_[isin]_[key]_index_9

pages_aktie_[isin]_[key]_index_10

pages_aktie_[isin]_[key]_index_14

Wann musste ich die Aktien von Acceleron Pharma kaufen, um die vorherige Dividende zu erhalten?

pages_aktie_[isin]_[key]_index_15

pages_aktie_[isin]_[key]_index_16

pages_aktie_[isin]_[key]_index_18

pages_aktie_[isin]_[key]_index_19

pages_aktie_[isin]_[key]_index_20

pages_aktie_[isin]_[key]_index_21

pages_aktie_[isin]_[key]_index_22

components_kpi_Savingsplan_0

components_kpi_Savingsplan_3